While sodium–glucose cotransporter-2 inhibitors (SGLT2 inhibitors) have been associated with reduced cancer risk [26,27], insulin and SUs have been linked to increased risks of overall, pancreatic, and liver cancers [28,29]. Here, SLC5A2 is linked to cancer.